ENOBOSARM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H14F3N3O3
Molecular Weight	389.328
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@](O)(COC1=CC=C(C=C1)C#N)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F

InChI

InChIKey=JNGVJMBLXIUVRD-SFHVURJKSA-N

InChI=1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C19H14F3N3O3
Molecular Weight	389.328
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24490605https://www.ncbi.nlm.nih.gov/pubmed/19852734
Curator's Comment: Description was created using several sources including: https://www.ncbi.nlm.nih.gov/pubmed/23499390 | https://www.ncbi.nlm.nih.gov/pubmed/24490605 | https://www.ncbi.nlm.nih.gov/pubmed/24633910 | https://www.ncbi.nlm.nih.gov/pubmed/26393303

MK-2866 (Gtx-024) is a selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis. It is a non-steroidal agent with anabolic activity designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone's action, this agent may increase lean body mass, thereby ameliorating muscle wasting in the hypermetabolic state of cancer cachexia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen Receptor 167 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15987833	Modulator 817		3.8 nM [Ki]
Androgen Receptor 167 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26393303	Modulator 817		3.8 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 426 Sources: https://clinicaltrials.gov/ct2/show/NCT01616758	Primary	Phase II 1133	Unknown Approved Use Unknown
Muscle wasting in non-small cell lung cancer 1 Sources: https://clinicaltrials.gov/ct2/show/NCT01355484	Primary	Phase III 651	Unknown Approved Use Unknown
Cachexia related to cancer 1 Sources: https://clinicaltrials.gov/ct2/show/NCT00467844	Primary	Phase II 1133	Unknown Approved Use Unknown
Muscle wasting in non-small cell lung cancer 1 Sources: https://clinicaltrials.gov/ct2/show/NCT01355497	Primary	Phase III 651	Unknown Approved Use Unknown
Metastatic breast cancer 7 Sources: https://clinicaltrials.gov/ct2/show/NCT01616758	Primary	Phase II 1133	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
57.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27105861	3 mg 1 times / day single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:		ENOBOSARM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
779.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27105861	3 mg 1 times / day single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:		ENOBOSARM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27105861	3 mg 1 times / day single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:		ENOBOSARM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 mg 1 times / day multiple, oral Highest studied dose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22031847 Page: p.155	healthy, ADULT n = 24 Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/22031847 Page: p.155	Disc. AE: ALT increased... AEs leading to discontinuation/dose reduction: ALT increased (4.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/22031847 Page: p.155
3 mg 1 times / day multiple, oral Highest studied dose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23499390 Page: p.7	unhealthy, ADULT n = 54 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 54 Sources: https://pubmed.ncbi.nlm.nih.gov/23499390 Page: p.7	Sources: https://pubmed.ncbi.nlm.nih.gov/23499390 Page: p.7

AEs

AE	Significance	Dose	Population
ALT increased	4.2% Disc. AE	3 mg 1 times / day multiple, oral Highest studied dose Dose: 3 mg, 1 times / day Route: oral Route: multiple Dose: 3 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22031847 Page: p.155	healthy, ADULT n = 24 Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/22031847 Page: p.155

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1532 substrate 1670	inhibitor 1695 substrate 985	inhibitor 1789 substrate 1168

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2C19 1410 BCRP 678 OATP1B1 770	UGT1A8 282 CYP2C19 955 CYP1A2 1013 UGT2B7 387 UGT1A4 345 UGT1A6 306 UGT2B15 202 UGT1A10 289 UGT1A1 417 P-gp 1491

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	no [IC50 >10 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	no [IC50 >10 uM]
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	no [IC50 >10 uM]
OATP1B1 785	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/34164937/	no
BCRP 751	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	yes [IC50 1.31 uM]	yes (co-administration study) Comment: Increased rosubastatin Cmax and AUCinf by 29% and 18%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	yes [IC50 1.6 uM]	yes (co-administration study) Comment: Decreased celecoxib Cmax and AUCinf by 13% and 10%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/
CYP2C19 1484	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	yess [IC50 0.7 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1670	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	major	yes (co-administration study) Comment: Rifampicin decreased Cmax and AUCinf by 23% and 43%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/
UGT1A1 417	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	major	yes (co-administration study) Comment: Probenecid increased AUCinf by 50% and decreased Cmax by 6.7%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/
UGT2B7 387	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	major	yes (co-administration study) Comment: Probenecid increased AUCinf by 50% and decreased Cmax by 6.7%. Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/
CYP2C19 955	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	minor
CYP2D6 1168	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	minor
UGT1A10 289	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	minor
UGT1A4 345	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	minor
UGT1A6 306	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	minor
UGT1A8 282	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	minor
UGT2B15 202	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	minor
CYP1A2 1013	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	no
CYP2C9 985	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27105861/	no
P-gp 1491	substrate 3264 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=174007253	no

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Enobosarm dosage of three soft gels once daily to equal 9mg

Route of Administration: Oral

In Vitro Use Guide

Enobosarm at the concentration of 10 nM modulates the transcriptional activity of AR in CV-1 cells cotransfected with a human AR expression vector, a luciferase reporter vector, and a control β-galactosidase vector, with 94%-100% relative activity of the transcriptional activation observed for 1 nM DHT.

Substance Class	Chemical Created by `admin` on `Sun Dec 18 19:25:56 UTC 2022` Edited by `admin` on `Sun Dec 18 19:25:56 UTC 2022`
Record UNII	O3571H3R8N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENOBOSARM

Official Name

English

PROPANAMIDE, 3-(4-CYANOPHENOXY)-N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-2-HYDROXY-2-METHYL-, (2S)-

Systematic Name

English

ENOBOSARM [USAN]

Common Name

English

GTX-024

Code

English

enobosarm [INN]

Common Name

English

Enobosarm [WHO-DD]

Common Name

English

OSTARINE

Brand Name

English

MK-2866

Code

English

Classification Tree Code System Code

DSLD

3985 (Number of products:13)